LY146032对癌症患者革兰氏阳性分离株的体外活性。

In-vitro activity of LY146032 against gram-positive isolates from cancer patients.

作者信息

Saito H, Rolston K V, Ho D H, LeBlanc B, Bodey G P

机构信息

Department of Medical Specialties, University of Texas M. D. Anderson Hospital and Tumor Institute, Houston 77030.

出版信息

J Antimicrob Chemother. 1987 Oct;20(4):497-503. doi: 10.1093/jac/20.4.497.

DOI:10.1093/jac/20.4.497

PMID:2824425

Abstract

The in-vitro activity of LY146032 was compared with that of other antibiotics against Gram-positive organisms, mostly isolated from cancer patients. LY146032 inhibited all isolates, including methicillin-resistant Staphylococcus aureus and Streptococcus faecalis, at a concentration of less than or equal to 2.0 mg/l. The MBCs of this new drug were within eight times the MICs for all bacteria tested.

摘要

将LY146032的体外活性与其他抗生素针对革兰氏阳性菌（大多从癌症患者体内分离得到）的活性进行了比较。LY146032在浓度小于或等于2.0毫克/升时，能抑制所有分离菌株，包括耐甲氧西林金黄色葡萄球菌和粪肠球菌。对于所有测试细菌，这种新药的最低杀菌浓度在最低抑菌浓度的八倍以内。